Trial Profile

A Phase I/II clinical trial of CTx001 in patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2025 New trial record
08 Oct 2025 According to Complement Therapeutics media release, the company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CTx001.
08 Oct 2025 According to Complement Therapeutics media release, the company announced that the trial will enrol patients across leading retinal centres with first patient dosing expected in the US in Q1 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com